A pilot study to evaluate stomach cancer risk reduction by Helicobacter pylori eradication [5]

American Journal of Gastroenterology

Volumn 97, Issue 3, 2002, Pages 764-765

  Hamajima, Nobuyuki ^a   Matuo, Keitaro ^a   Watanabe, Yoshihiro ^a   Suzuki, Takashi ^a   Nakamura, Tsuneya ^a   Matsuura, Akira ^a   Yamao, Kenji ^a   Ohashi, Kazuhiko ^a   Tominaga, Suketami ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE;

ADULT; ANTIBIOTIC THERAPY; ANTIBODY DETECTION; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERADICATION THERAPY; FOLLOW UP; GENETIC POLYMORPHISM; HELICOBACTER PYLORI; HUMAN; INCIDENCE; LETTER; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NATIONAL HEALTH INSURANCE; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLING; SERODIAGNOSIS; STOMACH CANCER;

EID: 0036129541     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(01)04133-8     Document Type: Letter

References (4)

1. Schistosomes, liver flukes and Helicobacter pylori
2. Helicobacter pylori and gastric cancer: Time for mega-trials?
3. Interleukin 1 polymorphisms, lifestyle factors, and Helicobacter pylori infection
4. Obstacles and their overcome in clinical intervention trial in Japan